인쇄하기
취소

4-way competition in NOAC market, well-played by Eliquis and Lixiana

Published: 2017-08-17 14:15:44
Updated: 2017-08-17 14:15:44

While 4 products are settled in the novel oral anticoagulant(NOAC) market, competition is expected to get fiercer.

Bayer’s Xarelto(rivaroxaban) gained the summit of the market; BMS’s Eliquis(apixaban) and a new strong competitor Daiichi Sankyo’s Lixiana(edoxaban) continued a growth; Boehringer Ingelheim’s Pradaxa(dabigatran) recorded a relatively poor performance.

According to the industry co...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.